Salbutamol tolerability and efficacy in patients with spinal muscular atrophy type II

•Changes over an 18-month period in 48 patients with SMA type II were investigated.•Salbutamol might be helpful in the maintenance of motor function in SMA type II.•Benefit was observed in younger children, especially during the first 6 months.•The majority of patients of all ages referred some kind of subjective positive effect.•Salbutamol seemed safe and was well tolerated without serious side effects. Spinal muscular atrophy (SMA) is an autosomal recessive disease caused by homozygous deletions or loss-of-function mutations in SMN1, which result in a degeneration of motor neurons in the spinal cord and brain stem. Even without a randomized placebo-controlled trial, salbutamol has been offered to patients with SMA in the neuromuscular clinics of most of hospitals for many years. We describe the response to salbutamol in 48 patients with SMA type II who were not taking any other medication. We investigate the changes over an eighteen-month period in motor functional scales and we analyze side effects and subjective response to treatment. Our results suggest that oral administration of salbutamol might be helpful in the maintenance of motor function in patients with SMA type II. An apparent beneficial effect was observed in functional scales of children under the age of 6, especially during the first 6 months of therapy. The majority of patients of all ages referred some kind of subjective positive effect associated with therapy intake. Salbutamol seemed safe and was well tolerated without serious side effects.